CVS Health Corporation (NYSE: CVS) delivered a robust first-quarter performance that exceeded Wall Street expectations, prompting management to lift its full-year adjusted earnings forecast. The company now projects 2026 adjusted earnings per share in the range of $7.30 to $7.50, up from its previous guidance of $7.00 to $7.20. The upgrade reflects improved cost management at its Aetna health insurance unit and stronger revenue across its healthcare services.
Q1 Financial Highlights
For the three months ended March 31, 2026, CVS reported total revenue of $100.43 billion, a 6.2% increase year-over-year. On a GAAP basis, diluted earnings per share came in at $2.30. Adjusted EPS, which excludes certain one-time items and accounting adjustments, rose to $2.57 from $2.25 in the same period last year. The results marked CVS's fifth consecutive quarterly earnings beat, according to Reuters.
Aetna's Cost Control Drives Improvement
The standout performer was CVS's Health Care Benefits segment, which houses the Aetna insurance business. Adjusted operating income for the segment surged 52.6% year-over-year to $3.04 billion. A key metric, the medical benefit ratio (MBR)—the portion of premiums spent on medical claims—dropped to 84.6% from 87.3% a year earlier. A lower MBR indicates better cost control and higher profitability. Chief Financial Officer Brian Newman told Reuters that improved forecasting capabilities helped the company anticipate cost trends more accurately.
Market Reaction
Investors responded enthusiastically, sending CVS shares up roughly 9% in early trading on Wednesday to $88.21, a gain of $7.52. The rally lifted the stock and contributed to a broader recovery in managed-care names. The positive sentiment reflected confidence in CVS's ability to stabilize its insurance operations after a period of elevated Medicare Advantage costs and executive turnover.
Segment Performance
CVS's Health Services segment, which includes its pharmacy benefit manager (PBM) Caremark, generated $48.24 billion in revenue, an 11% increase. However, segment profit fell 7.1% as improved client pricing was partially offset by favorable drug mix and purchasing economics. The Pharmacy & Consumer Wellness segment posted nearly flat revenue of $31.99 billion, while adjusted operating income dropped 8.8% due to reimbursement pressures, higher business investments, lighter seasonal illness trends, and weather-related disruptions. Prescription volume received a boost from the acquisition of select Rite Aid assets.
Outlook and Risks
CEO David Joyner attributed the strong quarter to "strong execution across our enterprise" and cited improvements in Health Care Benefits and Pharmacy & Consumer Wellness as key drivers. Nevertheless, the company maintained a cautious stance for the remainder of the year, citing persistently high cost trends. The Medicare Advantage sector remains a significant overhang, as insurers like Aetna, UnitedHealth, and Humana grapple with elevated claims usage. In April, the Centers for Medicare & Medicaid Services projected a 2.48% increase in 2027 Medicare Advantage payments, adding over $13 billion in new funding, but uncertainty persists about whether that will be sufficient to cover rising medical costs.
CVS acknowledged in its most recent 10-Q filing that no major updates to existing risk factors were made, but warned that higher medical utilization or further pharmacy reimbursement pressures could squeeze margins, impact cash flow, or weigh on the stock price.
